Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development (GEN3G)
|ClinicalTrials.gov Identifier: NCT01623934|
Recruitment Status : Active, not recruiting
First Posted : June 20, 2012
Last Update Posted : May 4, 2017
This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3 and 5 year after delivery.
The purpose of this phase 1 is to :
- assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
- assess levels of maternal adipokines as determinants of development and fetal growth;
- determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.
The purpose of this phase 2 is to:
- identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
- identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
- establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
- identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3 and 5 years of age.
|Condition or disease|
|Gestational Diabetes Insulin Resistance|
|Study Type :||Observational|
|Actual Enrollment :||1086 participants|
|Official Title:||Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||May 2019|
|Phase 1: Pregnant women|
|Phase 2: Mother-offspring dyad|
- Diagnosis of gestational diabetes mellitus [ Time Frame: 24-28 weeks of gestation ]75g oral glucose tolerance test
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623934
|Centre de recherche Étienne-Le Bel, Centre hospitalier universitaire de Sherbrooke|
|Sherbrooke, Quebec, Canada, J1H5N4|
|Principal Investigator:||Marie-France Hivert, MD, MSc||Université de Sherbrooke|